Talimogene laherparepvec
- Generic Name
- Talimogene laherparepvec
- Brand Names
- Imlygic
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1187560-31-1
- Unique Ingredient Identifier
- 07730V90L6
- Background
Talimogene laherparepvec is an oncolytic treatment used in local treatment of unresectable cutaneous, subcutaneous, and nodal lesions in patients with recurrent melanoma. It is a genetically administered herpes simplex virus 1 (HSV-1) that expresses human cytokine granulocyte-macrophage colony stimulating factor (GM-CSF) with antitumor and immune-stimulating...
- Indication
This medication is a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable, cutaneous, subcutaneous, and nodal lesions in patients with melanoma recurrent after initial surgery . Elsewhere, the EMA notes that the agent is indicated for the treatment of adults with unresectable melanoma that is regionally or distantly ...
- Associated Conditions
- Unresectable Skin Lesion
- Associated Therapies
- -
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
- Conditions
- Interventions
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2024-10-28
- Lead Sponsor
- John Rieth
- Target Recruit Count
- 30
- Registration Number
- NCT06660810
- Locations
- 🇺🇸
University of Iowa, Iowa City, Iowa, United States
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- John Rieth
- Target Recruit Count
- 8
- Registration Number
- NCT04599062
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Neoadjuvant T-VEC in High Risk Early Melanoma
- First Posted Date
- 2020-06-11
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- University of California, Davis
- Target Recruit Count
- 6
- Registration Number
- NCT04427306
- Locations
- 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2023-10-04
- Lead Sponsor
- The Netherlands Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT04330430
- Locations
- 🇳🇱
Antoni van Leeuwenhoek ziekenhuis, Amsterdam, NH, Netherlands
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Amgen
- Target Recruit Count
- 72
- Registration Number
- NCT04068181
- Locations
- 🇺🇸
New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸United States Oncology Regulatory Affairs Corporate Office, The Woodlands, Texas, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
Phase II Multicenter Study of Talimogene Laherparepvec in Classic or Endemic Kaposi Sarcoma
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2022-06-10
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 20
- Registration Number
- NCT04065152
- Locations
- 🇫🇷
Service de Dermatologie Hopital Saint-Louis, Paris, France
Study of T-VEC in Locally Advanced Cutaneous Angiosarcoma
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2022-11-01
- Target Recruit Count
- 5
- Registration Number
- NCT03921073
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- University of Louisville
- Target Recruit Count
- 28
- Registration Number
- NCT03842943
- Locations
- 🇺🇸
University of Louisville, Louisville, Kentucky, United States
Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies
- Conditions
- Interventions
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Dan Blazer III, M.D.
- Target Recruit Count
- 28
- Registration Number
- NCT03663712
- Locations
- 🇺🇸
University of Illinois College of Medicine at Chicago, Chicago, Illinois, United States
🇺🇸Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Study of Talimogene Laherparepvec (T-VEC) in Pancreatic Cancer
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Karie D. Runcie, MD
- Target Recruit Count
- 10
- Registration Number
- NCT03086642
- Locations
- 🇺🇸
Columbia University Medical Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.